Users Online: 1497 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Login 


RSACP wishes to inform that it shall be discontinuing the dispatch of print copy of JOACP to it's Life members. The print copy of JOACP will be posted only to those life members who send us a written confirmation for continuation of print copy.
Kindly email your affirmation for print copies to [email protected] preferably by 30th June 2019.

 

 
Table of Contents
LETTER TO EDITOR
Year : 2016  |  Volume : 32  |  Issue : 2  |  Page : 273-274

Heparin resistance during pediatric cardiac surgery: An unanticipated challenge for an anesthesiologist


1 Department of Anesthesia, Aga Khan University Hospital, Karachi, Pakistan
2 Department of Surgery, Aga Khan University Hospital, Karachi, Pakistan

Date of Web Publication10-May-2016

Correspondence Address:
Mohammad Irfan Akhtar
Department of Anesthesia, Aga Khan University, Stadium Road, Karachi
Pakistan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0970-9185.182123

Rights and Permissions

How to cite this article:
Akhtar MI, Ahmed SS, Sami SS. Heparin resistance during pediatric cardiac surgery: An unanticipated challenge for an anesthesiologist . J Anaesthesiol Clin Pharmacol 2016;32:273-4

How to cite this URL:
Akhtar MI, Ahmed SS, Sami SS. Heparin resistance during pediatric cardiac surgery: An unanticipated challenge for an anesthesiologist . J Anaesthesiol Clin Pharmacol [serial online] 2016 [cited 2021 May 7];32:273-4. Available from: https://www.joacp.org/text.asp?2016/32/2/273/182123

Sir,

A major challenge during cardiac surgery is to prevent thrombosis within the cardiopulmonary bypass (CPB) circuit. The coagulation system of the child and infant has been shown to be substantially different than that of the adult, and thus it requires special attention. The risks of CPB for this age group are inversely proportional to the child's age or weight. [1] Heparin has long been the anticoagulant of choice for initiation and maintenance of CPB because it is effective, inexpensive and can easily be reversed. [2]

Heparin resistance is defined as the inability to achieve an activated clotting time (ACT) >300 s after administration of >600 IU/kg heparin.

Anti-thrombin III (AT) concentrate if available is a better choice to build AT levels for heparin action as it requires smaller volume of fluid compared with a substantial volume load associated with FFP administration. [3]

Direct thrombin inhibitors are actually better inhibitors of CPB-induced anti-coagulation than heparin. Agents other than heparin have been used successfully to anticoagulate pediatric patients for CPB, but experience is scarce. The direct thrombin inhibitors r-hirudin, argatroban, and bivalirudin have all been used for CPB and are likely the best alternatives currently available. [4]

A 12-year-old child was scheduled for resection of the subaortic membrane. Baseline ACT was 128 s. After administration of 400 IU/kg of unfractionated heparin for going onto cardiopulmonary bypass, ACT did not rise above the baseline. The possible causes of heparin refractoriness, i.e., expired heparin, extravascular administration and ACT monitoring system malfunction, were ruled out. The patient was given the maximum allowable heparin dose of 600 IU/kg, but ACT increased to 160 s only. The patient was suspected to be having antithrombin III deficiency; hence, four units of fresh frozen plasma were transfused with the addition of 5000 IU of heparin afterward. Finally, ACT was done which increased to 750 s. The patient was put on CPB, and the membrane was resected through aortic root.

It was suggested to assess AT III deficiency in the patient to avoid complications in future cardiac surgery, but unfortunately, the child was lost to follow-up; therefore, the diagnosis remained to be confirmed.

Acknowledgment

Dr. Asma Hussain for proofing the scientific content.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
  References Top

1.
Eaton MP, Iannoli EM. Coagulation considerations for infants and children undergoing cardiopulmonary bypass. Paediatr Anaesth 2011;21:31-42.  Back to cited text no. 1
    
2.
Finley A, Greenberg C. Review article: Heparin sensitivity and resistance: Management during cardiopulmonary bypass. Anesth Analg 2013;116:1210-22.  Back to cited text no. 2
    
3.
Holness L, Knippen MA, Simmons L, Lachenbruch PA. Fatalities caused by TRALI. Transfus Med Rev 2004;18:184-8.  Back to cited text no. 3
    
4.
Riess FC, Poetzsch B, Madlener K, Cramer E, Doll KN, Doll S, et al. Recombinant hirudin for cardiopulmonary bypass anticoagulation: A randomized, prospective, and heparin-controlled pilot study. Thorac Cardiovasc Surg 2007;55:233-8.  Back to cited text no. 4
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
   References

 Article Access Statistics
    Viewed1737    
    Printed16    
    Emailed0    
    PDF Downloaded283    
    Comments [Add]    

Recommend this journal